Biogen Inc. said Thursday that it has settled a lawsuit with New Jersey-based Berlex Laboratories over a patent infringement claim related to Avonex, Biogen's flagship drug used to treat multiple sclerosis. Under the settlement agreement, Cambridge, Mass.-based Biogen will pay Berlex $20 million and receive a fully paid up, royalty-free, non-exclusive license under the patents held by Berlex.
January 24, 2002 at 12:00 AM
1 minute read
The original version of this story was published on Law.Com
Presented by BigVoodoo
This conference aims to help insurers and litigators better manage complex claims and litigation.
Recognizing innovation in the legal technology sector for working on precedent-setting, game-changing projects and initiatives.
Legalweek New York explores Business and Regulatory Trends, Technology and Talent drivers impacting law firms.
Description:NFSA has a great opportunity for a Labor Relations Associate and Junior Counsel. This position will support NFSA's collective ba...
McCarter & English, LLP is seeking litigation attorneys for our Newark, NJ offices. Candidates must have 3-6 years of law firm experien...
McCarter & English, LLP is actively seeking a corporate associate for its office located in Boston, MA. Candidate must have 2 - 5 years ...
